171 filings
Page 6 of 9
8-K
hvjkx
15 Apr 20
Treating Metabolic Acidosis and Slowing the Progression of Chronic Kidney Disease Investor Presentation April 2020
12:00am
8-K
b8ky7s2c
16 Mar 20
Departure of Directors or Certain Officers
4:11pm
S-8
ooe mwg79zg
2 Mar 20
Registration of securities for employees
4:12pm
8-K
nba4y9 2fp4nix68
28 Feb 20
Departure of Directors or Certain Officers
4:12pm
8-K
a88b4yz5qplwuo
27 Feb 20
Tricida Announces Fourth Quarter and Full-Year 2019 Financial Results
4:11pm
8-K
3utwjihstaao 6bc
13 Jan 20
Regulation FD Disclosure
8:02am
8-K
p83h55c
18 Dec 19
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
12:00am
8-K
3uwr3 nspng
14 Nov 19
Tricida Announces Third Quarter 2019 Financial Results
4:34pm
8-K
qq1glauawi1h cbj83
15 Oct 19
Regulation FD Disclosure
8:03am
8-K
9ie 40gonknqolfjzqta
10 Oct 19
Entry into a Material Definitive Agreement
4:25pm
8-K
laipujwjplujj 8ftv5o
4 Sep 19
Tricida Announces Submission of New Drug Application for Veverimer for the Treatment of Metabolic Acidosis in Patients with Chronic Kidney Disease
9:27am
8-K
pfea4ph
19 Aug 19
Entry into a Material Definitive Agreement
4:19pm
S-3ASR
9pn70mr
9 Aug 19
Automatic shelf registration
4:21pm
S-8
f529lrs97zch9 vkim
9 Aug 19
Registration of securities for employees
4:16pm
8-K
gvqeac
8 Aug 19
Tricida Announces Second Quarter 2019 Financial Results
4:08pm
8-K
htok0d4a5 tdtp3v85u7
25 Jun 19
Tricida Announces Publication of Positive Long-Term Phase 3 Clinical Trial Results of Veverimer (TRC101) in The Lancet
8:35am
8-K
0s88d3embylpxppfuic
31 May 19
Submission of Matters to a Vote of Security Holders
4:39pm